期刊文献+

EORTC评分系统在2μm激光与TUR-Bt治疗非肌层浸润性膀胱癌预后预测中的对照研究 被引量:2

A comparative study of recurrence and progression in non-muscle-invasive bladder tumor after 2 μm continuous-wave thulium laser or transurethral resection using european transurethral resection organization of research and treatment of cancer scoring syst
原文传递
导出
摘要 目的评估欧洲癌症研究与治疗组织风险评分表(EORTC)在2μm激光与经尿道膀胱肿瘤电切术(TUR-Bt)治疗非肌层浸润性膀胱癌(NMIBT)预后判断的价值。方法对2009年3月至2011年12月间在我院行经尿道膀胱肿物切除术的98例患者进行EORTC评分,其中56例患者行TUR-Bt术,42例行2μm激光肿瘤切除术,结合随访资料,回顾性分析EORTC在两种手术方式治疗NMIBT术后预测复发与进展方面的差异。结果 98例研究对象中1年内复发39例,其中TUR-Bt组23例(41.1%),2μm激光组16例(38.1%)。研究对象中1年内进展9例,其中TUR-Bt组6例(10.7%),2μm激光组3例(7.1%)。TUR-Bt组与2μm激光中实际复发或进展率与EORTC预测复发或进展率基本吻合,无统计学差异(P>0.05)。EORTC在两种手术术后预测复发与进展方面无统计学差异(P>0.05)。结论 EORTC预测体系能对NMIBT术后的临床预后进行较准确的预测,在2μm激光术中的应用价值,扩展了改预测体系的应用范围,是一种新的、极具潜力的预后判断手段。 Objective To assess the clinical prognostic value of European organization of research and treatment of cancer scoring system (EORTC) for non-muscle-invasive bladder tumor (NMIBT) after 2 μm continuous-wave thulium laser or transurethral resection (TUR-Bt). Methods Clinical data of 56 TUR-Bt cases and 42 2 μm continuous-wave thulium laser cases were scored with EORTC scoring system retrospectively, and confirmed the difference in recurrence and progression prediction of EORTC for NMIBT after 2 μm continuous-wave thulium laser and transurethral resection. Results There was no significant difference of recurrence and progression of NMIBT between the two groups (recurrence rate in 1 year: TUR-Bt group 41.1%, 2μm continuous-wave thulium laser group 38.1%; progression rate in 1 year: TUR-Bt group 10.7%, 2 μm continuous-wave thulium laser group 7.1%, P〉0.05). The recurrence and progression predicting risk of EORTC in TUR-Bt group and 2μm continuous-wave thulium laser group were coordinated with the real risks, with no significant difference (P〉0.05). No significant difference was found in recurrence and progression predicting risk of EORTC of the two groups(P〉0.05). Conclusions The EORTC scoring system can predict prognosis of NMIBT accurately, and has a promising clinical value in 2 μm continuous-wave thulium laser for NMIBT. It is a novel prognosis estmation method with much potential.
出处 《中华腔镜泌尿外科杂志(电子版)》 2013年第3期6-9,共4页 Chinese Journal of Endourology(Electronic Edition)
关键词 非肌层浸润性膀胱癌 经尿道膀胱肿瘤电切术 2ΜM激光 欧洲癌症研究与治 疗组织风险评分表 Non-muscle-invasive bladder tumor (NMIBT) Transurethral resection of bladdertumor(TUR-Bt) 2 μm continuous-wave thulium laser European organization of research and treatmentof cancer scoring system (EORTC)
  • 相关文献

参考文献13

二级参考文献71

  • 1MORGAN T M,CLARK P E.Bladder cancer[J].Curr Opin Oncol,2010,22(3):242-249.
  • 2WITJES J A,DOUGLASS J.The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer[J].Nat Clin Pract Urol,2007,4(10):542-549.
  • 3NIEDER A M,SIMON M A,KIM S S,et al.Radical cystectomy after bacillus Calmette-Guerin for high-risk Ta,T1,and carcinoma in situ:defining the risk of initial bladder preservation[J].Urology,2006,67:737-741.
  • 4KONETY B R.Molecular markers in bladder cancer:a critical appraisal[J].Urol Oncol,2006,24(4):326-337.
  • 5GROSSMAN H B,SOLOWAY M,MESSING E,et al.Surveillance for recurrent bladder cancer using a point-of-care proteomic assay[J].JAMA,2006,295(3):299-305.
  • 6BRAVACCINI S,SANCHINI M A,GRANATO A M,et al.Urine telomerase activity for the detection of bladder cancer in females[J].J Urol,2007,178(1):57-61.
  • 7SYLVESTER R J,VAN DER MEIJDEN A P,OOSTERLINCK W,et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials[J].Eur Urol,2006,49:466-475.
  • 8GREENE F L,PAGE D L,FLEMING I D,et al.AJCC Cancer Staging Manual[M].6th ed.New York:Springer Verlag:2002:199-202.
  • 9MOSTOFI F K,SORBIN L H,TORLONI H.Histological typing of urinary bladder tumors.International classification of tumors,No.10[M].WHO,Geneva,1973.
  • 10European Organization for Research and Treatment of Cancer[homepage on the Internet].EORTC risk tables for predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer[EB/OL].http://www.eortc.be/tools/bladdercalculator/(2011-4-17).

共引文献56

同被引文献21

  • 1沈肖曹,杜传军,史时芳,陈继民,经宵.经尿道钬激光切除与经尿道电切治疗浅表性膀胱肿瘤的疗效比较[J].中华泌尿外科杂志,2005,26(1):30-32. 被引量:42
  • 2朱生才,刘明,张耀光,朱刚,王建业,万奔.Ta期膀胱癌经尿道电切加膀胱内灌注治疗后的长期随访[J].中华泌尿外科杂志,2005,26(5):334-336. 被引量:13
  • 3蔡晨,孙颖浩,许传亮.非肌层浸润性膀胱癌经尿道切除术后复发和进展的风险预测[J].第二军医大学学报,2007,28(12):1365-1368. 被引量:8
  • 4郝捷,陈万青.膀胱癌-2012年中国肿瘤登记年报[R].北京:军事医学科学出版社,2012:97.
  • 5Divrik RT,Yildirim U,Zorlu F,et al.The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tu- mors of the bladder who received intravesical mltomycin: a prospec- tive,randomized clinical 3 trial[J]. J Ur01,2006,175(5):1641-1644.
  • 6Sylvester R J,Van-der-Meijden A P,Oosterlinck w,et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials[J]. Eur Uroi,2006,49:466- 475.
  • 7WITJES J A,DOUGLASS J.The role of hexaminolevulinate fluores- cence cystoscopy in bladder cancer[J].Nat Clin Pract Urol,2007,4 (10):542-549.
  • 8Kurth HW,Denis L, Sylvester R, et al.The natural history and the prognosis of treated superficial Bladder cancer.EORTC GU Group [J].Prog Clin Biol Res,1992, 378:1-7.
  • 9Nieder AM,Simon MA,Kim SS,et al.Radical cystectomy after bacil- lus Calmette-Guerin for high-risk Ta,Tl,and carcinoma in situ: de- fining the risk of initial bladder preservation[J]. Urology,2006,67: 737-741.
  • 10Hemandez V,Delapena E,Martin MD,et al.External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer[J].World .l Urol,2011,29(4): 409-414.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部